Pharmacy
The rule would allow CMS to have more insight into what the most expensive drugs on the market actually cost to manufacture and distribute.
Contracts with managed care plans would include a report on spread pricing, CMS says.
Patient demand could result in expanded coverage, but it could cost the federal program between $13.6 and $26.8 billion annually.
The House Committee on Oversight and Accountability will take up the role of pharmacy benefit managers on Tuesday, May 23.
If approved, Bertagnolli would oversee a $47B annual budget that funds biomedical research linked to half of the drugs approved by the FDA.
Its model combined precision patient recruitment from a diverse population and the delivery of hundreds of home clinical trials, the company says.
Medicare annual spending on lecanemab's medication costs alone would place it among the most expensive Part B medications.
Lawmakers expressed concern that the DEA's plan to roll back flexibilities could make OUD medication more difficult to obtain.
Still, Eli Lilly is touting the results, which demonstrate effectiveness at slowing the progression of the disease.
Both cite as a reason the implications of a court overriding drug decisions by the FDA.